Join Our Talent Community at ReCode Therapeutics (Menlo Park California, United States)

ReCode Therapeutics· Menlo Park California, United States·2h ago

Job description

Who We Are:

ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.

Don't see an opening that aligns with your expertise and interest? We encourage you to submit your resume, and let us know what areas you're interested in. We'll keep you informed of opportunities that arise in the future! Benefits Offered for Full-Time Employees:

No premium cost for employees - 100% subsidized by ReCode for full-time employees
Company 401k contribution
15 days of company paid holidays, including a holiday shutdown (usually the last week of the year)
Mental health support for employees & their families
FSA available, including a lifestyle spending account subsidized by company
Employee discounts at hotspots

ReCode Therapeutics (recodetx.com) offers a competitive compensation/benefits package with a friendly, collaborative culture that values employee engagement and ongoing career development.

ReCode Therapeutics is an Equal Opportunity Employer.

Why work at ReCode Therapeutics

Culture & Values: The company emphasizes “Patients First,” “Solve Together,” “Generate Audacious Science,” “Be Curious. Be Kind. Be Yourself,” “Act with Urgency,” and “Think It. Own It. Do It.” recodetx.com.
Work Environment: On-site in Menlo Park, CA. The culture is described as collaborative, with autonomy to drive change and a shared mission to transform genetic medicine.
Impact: Employees have the opportunity to work on a platform that could “fundamentally shift an entire class of medicine,” with a direct impact on patients with rare diseases.
Recognition: Consistently named a “Best Place to Work in the Bay Area.”
Engineering & Science Culture: Strong emphasis on cutting-edge science, with a team that includes experts from top biotech and pharma (Alector, Vertex, Genentech, etc.). The company actively hires for research, translational sciences, and chemistry roles.
Careers Page: Open positions are listed on Greenhouse. The company advises candidates to apply only through official channels and warns against recruitment scams.

About ReCode Therapeutics

Company Overview

One-liner: ReCode Therapeutics is a clinical-stage genetic medicines company using its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to develop mRNA and gene correction therapies for rare and genetically defined diseases.
Entity Type: Private (Series B; last disclosed round in September 2023)
Headquarters: Menlo Park, California, United States
Founded: 2015
Founders: Daniel J. Siegwart, Ph.D. (co-founder) – also the inventor of the SORT LNP platform

Core Business

Primary industry: Biotechnology / Genetic Medicines
Target customers: Patients with rare genetic diseases (e.g., cystic fibrosis, primary ciliary dyskinesia); the company operates in a B2B2C model, partnering with foundations and academic institutions while ultimately serving patients.
Mission: To power the next wave of genetic medicines by overcoming delivery limitations, enabling disease-modifying mRNA and gene correction therapeutics for conditions with few or no current treatment options.

Products & Services

SORT LNP Platform: A next-generation lipid nanoparticle delivery system that adds a fifth, distinct lipid to conventional LNPs, enabling precise delivery of genetic medicines (mRNA, gene correction payloads) to organs and tissues beyond the liver. Described by Nature as one of the “Seven Technologies to Watch in 2022” recodetx.com.
RCT2100 (Cystic Fibrosis): An inhaled LNP/mRNA-based therapy targeting the underlying cause of CF, developed in collaboration with the Cystic Fibrosis Foundation. The company is also pursuing gene correction approaches for CF.
Primary Ciliary Dyskinesia (PCD) Program: An mRNA-based therapy designed to restore ciliary function in the lungs of people with PCD caused by pathogenic mutations in the DNAI1 gene.
Future Indications: Expanding pipeline to include therapies for musculoskeletal, central nervous system, liver, and infectious disease indications.

Market Standing

Valuation: Not publicly disclosed.
Key Metric: Total funding of $386.9 million across multiple rounds (as of September 2023) linkedin.com. Annual revenue estimated at $16 million (LinkedIn data).
Notable Investors/Partners: EcoR1 Capital, Pfizer Venture Investments, Leaps by Bayer, Matrix Capital Management, OrbiMed, Colt Ventures, and the Cystic Fibrosis Foundation.
Growth Signals:
- Advancing lead programs into clinical development (CF and PCD).
- Expanded leadership team with experienced rare disease drug developers (e.g., CEO Shehnaaz Suliman, former COO of Alector; Chief Scientific Officer Jessica Couch, Ph.D.; Chief Medical Officer John G. Matthews, MBBS, MRCP, Ph.D.).
- Recognized as one of the “Best Places to Work in the Bay Area” (multiple years) recodetx.com.
- Headcount of approximately 48 employees (LinkedIn data, as of mid-2026), with a noted year-over-year decline of ~46% – likely reflecting a strategic restructuring or shift toward clinical-stage operations.

Competitive Advantages

SORT LNP Platform: The only LNP technology that can be tuned to deliver genetic medicines to specific organs and cells beyond the liver, overcoming the primary limitation of conventional LNPs.
Versatile payload and route compatibility: Can package mRNA, gene editing tools, and other nucleic acids, and be administered via inhalation, intravenous, or other routes.
First-in-class potential: Lead programs address rare diseases with no approved therapies (e.g., PCD) or significant unmet need (CF).
Strong intellectual property and academic roots: Platform invented at UT Southwestern Medical Center; co-founder Dr. Siegwart is a leading figure in non-viral delivery.

Strategic Focus

Advancing to the clinic: Moving lead CF and PCD programs into human clinical trials.
Platform expansion: Applying SORT LNP technology to new organs, diseases, and cargo types (gene correction, siRNA, etc.).
Scaling manufacturing and CMC: Building internal capabilities for process development and clinical manufacturing, led by SVP Vladimir Kharitonov, Ph.D.
Partnerships and collaborations: Leveraging relationships with the Cystic Fibrosis Foundation and other stakeholders to accelerate development.

Sources

Job description

Why work at ReCode Therapeutics

Application questions